Acute hepatitis C among Japanese hemodialysis patients

A prospective 9-year study

Norihiro Furusyo, Jun Hayashi, Kyoji Kakuda, Iwao Ariyama, Yoko Kanamoto-Tanaka, Chie Shimizu, Yoshitaka Etoh, Masaru Shigematsu, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

OBJECTIVES: The aims of this prospective survey were to determine the incidence and clinical characteristics of newly acquired hepatitis C virus (HCV) infection in hemodialysis patients after the start of antibody to HCV (anti-HCV) screening for blood products in Japan in 1989. METHODS: In serial serum samples from 269 hemodialysis patients who were followed over a mean period of 6.6 yr (± 2.1 yr) from 1990 to 1998, HCV RNA and anti-HCV were detected by reverse transcription-polymerase chain reaction and second generation ELISA, respectively. RESULTS: During the observation period, newly acquired HCV infection was found in 26 (15.4%) of the 169 hemodialysis patients without anti-HCV or HCV RNA at entry, an annual incidence rate of 2.59%. Of these 26, only four had a history of blood transfusion, one of whom had received the blood transfusion after 1992, the year in which screening of blood products for anti-HCV by second-generation ELISA was introduced in Japan. Persistent HCV viremia was found in 17 (65.4%) of the 26 patients; the other nine (34.6%) had transient HCV infection. The mean period of continuous ALT abnormality was significantly longer in the former (12.4 ± 13.6 months) than in the latter (1.9 ± 3.5 months) (p = 0.0067). However, only three (17.6%) of 17 patients with chronic HCV viremia had continuous ALT abnormality for more than 24 months; in all of them, ALT eventually normalized. CONCLUSIONS: These findings indicate that newly acquired HCV infection has continued to occur in hemodialysis patients after the initiation of anti-HCV screening of blood products and that the abnormal ALT found in these patients is related to HCV chronicity.

Original languageEnglish
Pages (from-to)1592-1600
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume96
Issue number5
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

Hepatitis C
Hepacivirus
Renal Dialysis
Hepatitis C Antibodies
Virus Diseases
Viremia
Blood Transfusion
Japan
Enzyme-Linked Immunosorbent Assay
RNA
Incidence
Chronic Hepatitis C
Reverse Transcription
Observation
Polymerase Chain Reaction
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Furusyo, N., Hayashi, J., Kakuda, K., Ariyama, I., Kanamoto-Tanaka, Y., Shimizu, C., ... Kashiwagi, S. (2001). Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. American Journal of Gastroenterology, 96(5), 1592-1600. https://doi.org/10.1016/S0002-9270(01)02264-X

Acute hepatitis C among Japanese hemodialysis patients : A prospective 9-year study. / Furusyo, Norihiro; Hayashi, Jun; Kakuda, Kyoji; Ariyama, Iwao; Kanamoto-Tanaka, Yoko; Shimizu, Chie; Etoh, Yoshitaka; Shigematsu, Masaru; Kashiwagi, Seizaburo.

In: American Journal of Gastroenterology, Vol. 96, No. 5, 01.01.2001, p. 1592-1600.

Research output: Contribution to journalArticle

Furusyo, N, Hayashi, J, Kakuda, K, Ariyama, I, Kanamoto-Tanaka, Y, Shimizu, C, Etoh, Y, Shigematsu, M & Kashiwagi, S 2001, 'Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study', American Journal of Gastroenterology, vol. 96, no. 5, pp. 1592-1600. https://doi.org/10.1016/S0002-9270(01)02264-X
Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C et al. Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. American Journal of Gastroenterology. 2001 Jan 1;96(5):1592-1600. https://doi.org/10.1016/S0002-9270(01)02264-X
Furusyo, Norihiro ; Hayashi, Jun ; Kakuda, Kyoji ; Ariyama, Iwao ; Kanamoto-Tanaka, Yoko ; Shimizu, Chie ; Etoh, Yoshitaka ; Shigematsu, Masaru ; Kashiwagi, Seizaburo. / Acute hepatitis C among Japanese hemodialysis patients : A prospective 9-year study. In: American Journal of Gastroenterology. 2001 ; Vol. 96, No. 5. pp. 1592-1600.
@article{211eba89a6424d3abbc8ab36ade25bbd,
title = "Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study",
abstract = "OBJECTIVES: The aims of this prospective survey were to determine the incidence and clinical characteristics of newly acquired hepatitis C virus (HCV) infection in hemodialysis patients after the start of antibody to HCV (anti-HCV) screening for blood products in Japan in 1989. METHODS: In serial serum samples from 269 hemodialysis patients who were followed over a mean period of 6.6 yr (± 2.1 yr) from 1990 to 1998, HCV RNA and anti-HCV were detected by reverse transcription-polymerase chain reaction and second generation ELISA, respectively. RESULTS: During the observation period, newly acquired HCV infection was found in 26 (15.4{\%}) of the 169 hemodialysis patients without anti-HCV or HCV RNA at entry, an annual incidence rate of 2.59{\%}. Of these 26, only four had a history of blood transfusion, one of whom had received the blood transfusion after 1992, the year in which screening of blood products for anti-HCV by second-generation ELISA was introduced in Japan. Persistent HCV viremia was found in 17 (65.4{\%}) of the 26 patients; the other nine (34.6{\%}) had transient HCV infection. The mean period of continuous ALT abnormality was significantly longer in the former (12.4 ± 13.6 months) than in the latter (1.9 ± 3.5 months) (p = 0.0067). However, only three (17.6{\%}) of 17 patients with chronic HCV viremia had continuous ALT abnormality for more than 24 months; in all of them, ALT eventually normalized. CONCLUSIONS: These findings indicate that newly acquired HCV infection has continued to occur in hemodialysis patients after the initiation of anti-HCV screening of blood products and that the abnormal ALT found in these patients is related to HCV chronicity.",
author = "Norihiro Furusyo and Jun Hayashi and Kyoji Kakuda and Iwao Ariyama and Yoko Kanamoto-Tanaka and Chie Shimizu and Yoshitaka Etoh and Masaru Shigematsu and Seizaburo Kashiwagi",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0002-9270(01)02264-X",
language = "English",
volume = "96",
pages = "1592--1600",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Acute hepatitis C among Japanese hemodialysis patients

T2 - A prospective 9-year study

AU - Furusyo, Norihiro

AU - Hayashi, Jun

AU - Kakuda, Kyoji

AU - Ariyama, Iwao

AU - Kanamoto-Tanaka, Yoko

AU - Shimizu, Chie

AU - Etoh, Yoshitaka

AU - Shigematsu, Masaru

AU - Kashiwagi, Seizaburo

PY - 2001/1/1

Y1 - 2001/1/1

N2 - OBJECTIVES: The aims of this prospective survey were to determine the incidence and clinical characteristics of newly acquired hepatitis C virus (HCV) infection in hemodialysis patients after the start of antibody to HCV (anti-HCV) screening for blood products in Japan in 1989. METHODS: In serial serum samples from 269 hemodialysis patients who were followed over a mean period of 6.6 yr (± 2.1 yr) from 1990 to 1998, HCV RNA and anti-HCV were detected by reverse transcription-polymerase chain reaction and second generation ELISA, respectively. RESULTS: During the observation period, newly acquired HCV infection was found in 26 (15.4%) of the 169 hemodialysis patients without anti-HCV or HCV RNA at entry, an annual incidence rate of 2.59%. Of these 26, only four had a history of blood transfusion, one of whom had received the blood transfusion after 1992, the year in which screening of blood products for anti-HCV by second-generation ELISA was introduced in Japan. Persistent HCV viremia was found in 17 (65.4%) of the 26 patients; the other nine (34.6%) had transient HCV infection. The mean period of continuous ALT abnormality was significantly longer in the former (12.4 ± 13.6 months) than in the latter (1.9 ± 3.5 months) (p = 0.0067). However, only three (17.6%) of 17 patients with chronic HCV viremia had continuous ALT abnormality for more than 24 months; in all of them, ALT eventually normalized. CONCLUSIONS: These findings indicate that newly acquired HCV infection has continued to occur in hemodialysis patients after the initiation of anti-HCV screening of blood products and that the abnormal ALT found in these patients is related to HCV chronicity.

AB - OBJECTIVES: The aims of this prospective survey were to determine the incidence and clinical characteristics of newly acquired hepatitis C virus (HCV) infection in hemodialysis patients after the start of antibody to HCV (anti-HCV) screening for blood products in Japan in 1989. METHODS: In serial serum samples from 269 hemodialysis patients who were followed over a mean period of 6.6 yr (± 2.1 yr) from 1990 to 1998, HCV RNA and anti-HCV were detected by reverse transcription-polymerase chain reaction and second generation ELISA, respectively. RESULTS: During the observation period, newly acquired HCV infection was found in 26 (15.4%) of the 169 hemodialysis patients without anti-HCV or HCV RNA at entry, an annual incidence rate of 2.59%. Of these 26, only four had a history of blood transfusion, one of whom had received the blood transfusion after 1992, the year in which screening of blood products for anti-HCV by second-generation ELISA was introduced in Japan. Persistent HCV viremia was found in 17 (65.4%) of the 26 patients; the other nine (34.6%) had transient HCV infection. The mean period of continuous ALT abnormality was significantly longer in the former (12.4 ± 13.6 months) than in the latter (1.9 ± 3.5 months) (p = 0.0067). However, only three (17.6%) of 17 patients with chronic HCV viremia had continuous ALT abnormality for more than 24 months; in all of them, ALT eventually normalized. CONCLUSIONS: These findings indicate that newly acquired HCV infection has continued to occur in hemodialysis patients after the initiation of anti-HCV screening of blood products and that the abnormal ALT found in these patients is related to HCV chronicity.

UR - http://www.scopus.com/inward/record.url?scp=0034997052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034997052&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(01)02264-X

DO - 10.1016/S0002-9270(01)02264-X

M3 - Article

VL - 96

SP - 1592

EP - 1600

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -